Minxian Wang1,2,3, Justin Chun1,2,4, Giulio Genovese5, Andrea U Knob1, Ava Benjamin1, Maris S Wilkins1, David J Friedman1,2, Gerald B Appel6, Richard P Lifton7, Shrikant Mane8, Martin R Pollak9,2,3. 1. Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 2. Department of Medicine, Harvard Medical School, Boston, Massachusetts. 3. Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts. 4. Division of Nephrology, Department of Medicine, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada. 5. Stanley Center for Psychiatric Research, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts. 6. Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. 7. Laboratory of Human Genetics and Genomics, The Rockefeller University, New York, New York; and. 8. Department of Genetics, Yale University School of Medicine, New Haven, Connecticut. 9. Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts; mpollak@bidmc.harvard.edu.
Abstract
BACKGROUND: Over the past two decades, the importance of genetic factors in the development of FSGS has become increasingly clear. However, despite many known monogenic causes of FSGS, single gene defects explain only 30% of cases. METHODS: To investigate mutations underlying FSGS, we sequenced 662 whole exomes from individuals with sporadic or familial FSGS. After quality control, we analyzed the exome data from 363 unrelated family units with sporadic or familial FSGS and compared this to data from 363 ancestry-matched controls. We used rare variant burden tests to evaluate known disease-associated genes and potential new genes. RESULTS: We validated several FSGS-associated genes that show a marked enrichment of deleterious rare variants among the cases. However, for some genes previously reported as FSGS related, we identified rare variants at similar or higher frequencies in controls. After excluding such genes, 122 of 363 cases (33.6%) had rare variants in known disease-associated genes, but 30 of 363 controls (8.3%) also harbored rare variants that would be classified as "causal" if detected in cases; applying American College of Medical Genetics filtering guidelines (to reduce the rate of false-positive claims that a variant is disease related) yielded rates of 24.2% in cases and 5.5% in controls. Highly ranked new genes include SCAF1, SETD2, and LY9. Network analysis showed that top-ranked new genes were located closer than a random set of genes to known FSGS genes. CONCLUSIONS: Although our analysis validated many known FSGS-causing genes, we detected a nontrivial number of purported "disease-causing" variants in controls, implying that filtering is inadequate to allow clinical diagnosis and decision making. Genetic diagnosis in patients with FSGS is complicated by the nontrivial rate of variants in known FSGS genes among people without kidney disease.
BACKGROUND: Over the past two decades, the importance of genetic factors in the development of FSGS has become increasingly clear. However, despite many known monogenic causes of FSGS, single gene defects explain only 30% of cases. METHODS: To investigate mutations underlying FSGS, we sequenced 662 whole exomes from individuals with sporadic or familial FSGS. After quality control, we analyzed the exome data from 363 unrelated family units with sporadic or familial FSGS and compared this to data from 363 ancestry-matched controls. We used rare variant burden tests to evaluate known disease-associated genes and potential new genes. RESULTS: We validated several FSGS-associated genes that show a marked enrichment of deleterious rare variants among the cases. However, for some genes previously reported as FSGS related, we identified rare variants at similar or higher frequencies in controls. After excluding such genes, 122 of 363 cases (33.6%) had rare variants in known disease-associated genes, but 30 of 363 controls (8.3%) also harbored rare variants that would be classified as "causal" if detected in cases; applying American College of Medical Genetics filtering guidelines (to reduce the rate of false-positive claims that a variant is disease related) yielded rates of 24.2% in cases and 5.5% in controls. Highly ranked new genes include SCAF1, SETD2, and LY9. Network analysis showed that top-ranked new genes were located closer than a random set of genes to known FSGS genes. CONCLUSIONS: Although our analysis validated many known FSGS-causing genes, we detected a nontrivial number of purported "disease-causing" variants in controls, implying that filtering is inadequate to allow clinical diagnosis and decision making. Genetic diagnosis in patients with FSGS is complicated by the nontrivial rate of variants in known FSGS genes among people without kidney disease.
Authors: J M Kaplan; S H Kim; K N North; H Rennke; L A Correia; H Q Tong; B J Mathis; J C Rodríguez-Pérez; P G Allen; A H Beggs; M R Pollak Journal: Nat Genet Date: 2000-03 Impact factor: 38.330
Authors: David G Clayton; Neil M Walker; Deborah J Smyth; Rebecca Pask; Jason D Cooper; Lisa M Maier; Luc J Smink; Alex C Lam; Nigel R Ovington; Helen E Stevens; Sarah Nutland; Joanna M M Howson; Malek Faham; Martin Moorhead; Hywel B Jones; Matthew Falkowski; Paul Hardenbol; Thomas D Willis; John A Todd Journal: Nat Genet Date: 2005-10-09 Impact factor: 38.330
Authors: Michelle P Winn; Peter J Conlon; Kelvin L Lynn; Merry Kay Farrington; Tony Creazzo; April F Hawkins; Nikki Daskalakis; Shu Ying Kwan; Seth Ebersviller; James L Burchette; Margaret A Pericak-Vance; David N Howell; Jeffery M Vance; Paul B Rosenberg Journal: Science Date: 2005-05-05 Impact factor: 47.728
Authors: Kirtida Mistry; James H E Ireland; Roland C K Ng; Joel M Henderson; Martin R Pollak Journal: Am J Kidney Dis Date: 2007-11 Impact factor: 8.860
Authors: Christian von Mering; Lars J Jensen; Berend Snel; Sean D Hooper; Markus Krupp; Mathilde Foglierini; Nelly Jouffre; Martijn A Huynen; Peer Bork Journal: Nucleic Acids Res Date: 2005-01-01 Impact factor: 16.971
Authors: Nicholas J Steers; Yask Gupta; Vivette D D'Agati; Tze Y Lim; Natalia DeMaria; Anna Mo; Judy Liang; Kelsey O Stevens; Dina F Ahram; Wan Yee Lam; Mihai Gagea; Lalitha Nagarajan; Simone Sanna-Cherchi; Ali G Gharavi Journal: J Am Soc Nephrol Date: 2021-12-10 Impact factor: 10.121
Authors: Samantha M Baxter; Jennifer E Posey; Nicole J Lake; Nara Sobreira; Jessica X Chong; Steven Buyske; Elizabeth E Blue; Lisa H Chadwick; Zeynep H Coban-Akdemir; Kimberly F Doheny; Colleen P Davis; Monkol Lek; Christopher Wellington; Shalini N Jhangiani; Mark Gerstein; Richard A Gibbs; Richard P Lifton; Daniel G MacArthur; Tara C Matise; James R Lupski; David Valle; Michael J Bamshad; Ada Hamosh; Shrikant Mane; Deborah A Nickerson; Heidi L Rehm; Anne O'Donnell-Luria Journal: Genet Med Date: 2022-02-09 Impact factor: 8.864
Authors: Mara Sanches Guaragna; Anna Cristina Gervásio de Brito Lutaif; Marcela Lopes de Souza; Andréa Trevas Maciel-Guerra; Vera Maria Santoro Belangero; Gil Guerra-Júnior; Maricilda Palandi de Mello Journal: Mol Genet Genomics Date: 2019-09-13 Impact factor: 3.291
Authors: Jose Lazaro-Guevara; Julio Fierro-Morales; A Hunter Wright; River Gunville; Christopher Simeone; Scott G Frodsham; Melissa H Pezzolesi; Courtney A Zaffino; Laith Al-Rabadi; Nirupama Ramkumar; Marcus G Pezzolesi Journal: Am J Nephrol Date: 2021-03-26 Impact factor: 3.754
Authors: Michael D Donnan; Rizaldy P Scott; Tuncer Onay; Antoine Tarjus; Ummiye Venus Onay; Susan E Quaggin Journal: Front Med (Lausanne) Date: 2019-08-27